Polaris Pharmaceuticals-KY: Shareholders Approve Lifting of Director Non-Competition Restrictions
NQ Score
50/100
AI Summary (NQ-processed)
Polaris Pharmaceuticals-KY announced that its shareholders' meeting held on May 15, 2026, approved the resolution to lift the non-competition restrictions for its new directors. The approved activities include investing in or operating businesses that are the same as or similar to the company's business scope. This waiver is effective from May 15, 2026, until the directors' term concludes. The decision was made in accordance with Article 209 of the Company Act.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What was decided at the shareholders' meeting of Polaris Pharmaceuticals-KY?
- A: The shareholders' meeting approved the lifting of non-competition restrictions for new directors.
- Q: Who are the directors permitted to engage in competitive activities?
- A: The directors permitted are Chen Xian-zhe, Digital Capital Inc. (represented by Wei Shao-jun), and Mai Investment Co., Ltd. (represented by Cai Gao-zhong).
- Q: What kind of competitive activities are permitted?
- A: Directors are permitted to invest in or operate businesses that are the same as or similar to the company's business scope.
- Q: What is the duration of the permitted non-competition waiver?
- A: The waiver is effective from May 15, 2026, until their term as director ends.